Think twice, ask one: reducing preventable waste in theatre QP Case Study January 2017
KTT19: Psychotropic medicines in people with learning disabilities whose behaviour challenges Key Therapeutic Topic January 2017 Unclassified
KTT21: Medicines optimisation in long-term pain Key Therapeutic Topic January 2017 Unclassified
KTT18: Multimorbidity and polypharmacy Key Therapeutic Topic January 2017 Unclassified
KTT20: Safer insulin prescribing Key Therapeutic Topic January 2017 Unclassified
Antibiotic prophylaxis against infective endocarditis is not recommended routinely[1]: for people undergoing dental procedures for people undergoing non-dental procedures at the following sites[2]: upper and lower gastrointestinal tract genitourinary tract; this includes urological, gynaecological and obstetric procedures, and childbirth upper and lower respiratory tract; this includes ear, nose and throat procedures and bronchoscopy. Do not do recommendation December 2016
Alirocumab is not recommended for treating non-familial hypercholesterolaemia or mixed dyslipidaemia in adults without a history of cardiovascular disease. Do not do recommendation December 2016
Do not offer nicotinic acid (niacin) for the prevention of CVD to any of the following: people who are being treated for primary prevention, people who are being treated for secondary prevention, people with CKD, people with type 1 diabetes, people with type 2 diabetes. Do not do recommendation December 2016
Children with bronchiolitis are not prescribed antibiotics to treat the infection. Do not do recommendation December 2016
A fasting sample is not required when taking samples before starting lipid modification therapy for the primary prevention of CVD. Take at least 1 lipid sample to measure a full lipid profile. Do not do recommendation December 2016